Akums Drugs’ key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Job Work and Scrap for the year ending 31-Mar-2023.
Financials
For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 1073.09 crore, up 4.69% from last quarter Total Income of Rs 1024.97 crore and up 12.43% from last year same quarter Total Income of Rs 954.45 crore. The company has reported net profit after tax of Rs 149.61 crore in the latest quarter. The company’s top management includes Mr.Sanjeev Jain, Mr.Sandeep Jain, Mr.Sanjay Sinha, Mr.Sunil Kumar Thakur, Ms.Matangi Gowrishankar, Mr.Kewal Kundanlal Handa, Mr.Nand Lal Kalra, Mr.Satwinder Singh. Company has Walker Chandiok & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 16 crore shares outstanding.
Investment Rationale
ICICI Securities expects Akums to post revenue EBITDA/PAT CAGR of 13.2%/ 24.8%/20.1% over FY25?27E with 242bps jump in EBITDA margin to 13.6% in FY27E. At CMP, the stock trades at 25.3x/19.1x FY26/ FY27E EPS of Rs 22.8/ Rs 30.3, respectively. The brokerage maintains BUY with SoTP-based unchanged target price of Rs 710. Key downside risks: Location concentration of manufacturing plants, fluctuation in API prices. Promoter/FII Holdings
Promoters held 75.26 per cent stake in the company as of 31-Mar-2025, while FIIs owned 5.77 per cent, DIIs 7.39 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.